FIRST QUARTER IN BRIEF
- Dr.
Erik Vahtola appointed Chief Medical Officer (Jan 01 ) - First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (
Feb 07 ) Active Biotech entered into global patent license agreement withOncode Institute for tasquinimod in myelofibrosis (Feb 9 )
EVENTS AFTER THE END OF THE PERIOD
- Laquinimod eye drop phase I single ascending-dose part in healthy subjects finished with no safety concerns, multiple-dose part started
Financial summary
SEK M | Jan-Mar | Full-year | |||
2022 | 2021 | 2021 | |||
Net sales | - | - | - | ||
Operating loss/loss | -15,3 | -9,7 | -49,8 | ||
Profit/loss after tax | -15,7 | -9,8 | -49,8 | ||
Earnings per share (SEK) | -0,07 | -0,05 | -0,24 | ||
Cash and cash equivalents (at close of period) | 37,8 | 92,0 | 53,1 | ||
For further information, please contact:
Helén Tuvesson, CEO Tel: +46 (0)46 19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | (Corp. Reg. No. 556223-9227) Scheelevägen 22, SE-223 63 Lund Tel: +46 (0)46 19 20 00 |
The report is also available at www.activebiotech.com.
Attachment
- 220421_Active Biotech Interim Report Q1
© OMX, source